Sebastian J Reinstadler1, Martin Reindl1, Hans-Josef Feistritzer1, Gert Klug1, Agnes Mayr2, Markus Kofler3, Alexander Minh-Duc Tu1, Luc Huybrechts1, Johannes Mair1, Wolfgang-Michael Franz1, Bernhard Metzler4. 1. University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. 2. Department of Radiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. 3. Department of Cardiac Surgery, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. 4. University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. Bernhard.Metzler@uki.at.
Abstract
BACKGROUND: In patients with ST-elevation myocardial infarction (STEMI), the relationship between transaminases and myocardial damage detected by cardiac magnetic resonance (CMR) imaging is unknown and the prognostic value incompletely investigated. MATERIALS AND METHODS: CMR imaging was performed in 167 STEMI patients 2.3 [1.6-3.9] days after primary percutaneous coronary intervention (PPCI). Blood samples for transaminase measurement (aspartate transaminase (AST) and alanine transaminase (ALT)) were obtained serially from day 1 to day 4 after PPCI. Patients were followed for major adverse cardiac events (MACE) for 2.7 [1.1-3.3] years. RESULTS: Admission and peak concentrations of AST and ALT were significantly associated with ejection fraction (p < 0.001), infarct size (p < 0.001), and the presence of microvascular obstruction (p < 0.01). Peak values of both transaminases showed a stronger correlation with CMR parameters than admission values (all p < 0.05). In Kaplan-Meier analysis, a high peak AST or high peak ALT was associated with reduced MACE-free survival (both p < 0.01), whereas admission values were not (both p > 0.05). Peak AST (hazard ratio (HR): 4.93 [1.70-14.32], p = 0.003) and peak ALT (HR: 5.67 [1.94-16.56], p = 0.002) were independent predictors of MACE after adjusting for clinical risk factors. CONCLUSIONS: Transaminases measured in the acute phase after PPCI for STEMI are associated with systolic dysfunction, more extensive myocardial necrosis and microvascular injury with subsequent prognostic information on MACE at long-term follow-up.
BACKGROUND: In patients with ST-elevation myocardial infarction (STEMI), the relationship between transaminases and myocardial damage detected by cardiac magnetic resonance (CMR) imaging is unknown and the prognostic value incompletely investigated. MATERIALS AND METHODS: CMR imaging was performed in 167 STEMI patients 2.3 [1.6-3.9] days after primary percutaneous coronary intervention (PPCI). Blood samples for transaminase measurement (aspartate transaminase (AST) and alanine transaminase (ALT)) were obtained serially from day 1 to day 4 after PPCI. Patients were followed for major adverse cardiac events (MACE) for 2.7 [1.1-3.3] years. RESULTS: Admission and peak concentrations of AST and ALT were significantly associated with ejection fraction (p < 0.001), infarct size (p < 0.001), and the presence of microvascular obstruction (p < 0.01). Peak values of both transaminases showed a stronger correlation with CMR parameters than admission values (all p < 0.05). In Kaplan-Meier analysis, a high peak AST or high peak ALT was associated with reduced MACE-free survival (both p < 0.01), whereas admission values were not (both p > 0.05). Peak AST (hazard ratio (HR): 4.93 [1.70-14.32], p = 0.003) and peak ALT (HR: 5.67 [1.94-16.56], p = 0.002) were independent predictors of MACE after adjusting for clinical risk factors. CONCLUSIONS: Transaminases measured in the acute phase after PPCI for STEMI are associated with systolic dysfunction, more extensive myocardial necrosis and microvascular injury with subsequent prognostic information on MACE at long-term follow-up.
Entities:
Keywords:
Cardiac magnetic resonance; Major adverse cardiac events; Myocardial infarction; Prognosis; Transaminases
Authors: Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: David M Lofthus; Susanna R Stevens; Paul W Armstrong; Christopher B Granger; Kenneth W Mahaffey Journal: Coron Artery Dis Date: 2012-01 Impact factor: 1.439
Authors: Tomas Jernberg; Per Johanson; Claes Held; Bodil Svennblad; Johan Lindbäck; Lars Wallentin Journal: JAMA Date: 2011-04-27 Impact factor: 56.272
Authors: Sebastian Johannes Reinstadler; Gert Klug; Hans-Josef Feistritzer; Agnes Mayr; Bettina Harrasser; Johannes Mair; Kerstin Bader; Katrin Streil; Angelika Hammerer-Lercher; Regina Esterhammer; Bernhard Metzler Journal: Heart Date: 2013-05-22 Impact factor: 5.994
Authors: Gert Klug; Thomas Trieb; Michael Schocke; Michael Nocker; Elisabeth Skalla; Agnes Mayr; Martha Nowosielski; Kathrin Pedarnig; Thomas Bartel; Nico Moes; Otmar Pachinger; Bernhard Metzler Journal: J Magn Reson Imaging Date: 2009-02 Impact factor: 4.813
Authors: Sebastian Johannes Reinstadler; Hans-Josef Feistritzer; Martin Reindl; Gert Klug; Agnes Mayr; Johannes Mair; Werner Jaschke; Bernhard Metzler Journal: Open Heart Date: 2016-09-20
Authors: Tamás Horváth; Gyöngyi Serfőző; Ádám Györkei; Imre Földesi; Tamás Forster; Margit Keresztes Journal: PLoS One Date: 2019-04-11 Impact factor: 3.240
Authors: Eugenia B Manukhina; Vadim E Tseilikman; Marina N Karpenko; Nina S Pestereva; Olga B Tseilikman; Maria V Komelkova; Marina V Kondashevskaya; Anna V Goryacheva; Maxim S Lapshin; Pavel O Platkovskii; Alexey P Sarapultsev; Anatoly V Alliluev; H Fred Downey Journal: Int J Mol Sci Date: 2020-01-05 Impact factor: 5.923